Education
About Us
Working with TipRanks
Follow Us
NATCO Pharma Limited (IN:NATCOPHARM)
:NATCOPHARM
NATCOPHARM Stock Chart & Stats
Day’s Range― - ―
52-Week Range₹660.05 - ₹1,638.35
Previous CloseN/A
Volume335.92K
Average Volume (3M)78.90K
Market Cap
₹174.95B
Enterprise Value₹162.22B
Total Cash (Recent Filing)₹24.63B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)9.3
Beta1.07
Next Earnings
Aug 06, 2025EPS Estimate
36.9Last Dividend Ex-Date
Feb 18, 2025Dividend Yield0.61%
Share Statistics
EPS (TTM)22.85
Shares Outstanding179,109,860
10 Day Avg. Volume110,143
30 Day Avg. Volume78,896
Financial Highlights & Ratios
PEG Ratio8.78
Price to Book (P/B)2.38
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,006.50Price Target Upside16.70% Upside
Rating ConsensusHold
Number of Analyst Covering0
NATCO Pharma Limited News
PremiumCompany Announcements
Natco Pharma Appoints New Senior VP of OperationsNATCOPHARM FAQ
What was NATCO Pharma Limited’s price range in the past 12 months?
NATCO Pharma Limited lowest stock price was ₹660.05 and its highest was ₹1638.35 in the past 12 months.
What is NATCO Pharma Limited’s market cap?
NATCO Pharma Limited’s market cap is ₹174.95B.
When is NATCO Pharma Limited’s upcoming earnings report date?
NATCO Pharma Limited’s upcoming earnings report date is Aug 06, 2025 which is in 19 days.
How were NATCO Pharma Limited’s earnings last quarter?
NATCO Pharma Limited released its earnings results on May 28, 2025. The company reported ₹22.85 earnings per share for the quarter, beating the consensus estimate of ₹10.8 by ₹12.05.
Is NATCO Pharma Limited overvalued?
According to Wall Street analysts NATCO Pharma Limited’s price is currently Undervalued.
Does NATCO Pharma Limited pay dividends?
NATCO Pharma Limited pays a Quarterly dividend of ₹6 which represents an annual dividend yield of 0.61%. See more information on NATCO Pharma Limited dividends here
What is NATCO Pharma Limited’s EPS estimate?
NATCO Pharma Limited’s EPS estimate is 36.9.
How many shares outstanding does NATCO Pharma Limited have?
NATCO Pharma Limited has 179,109,860 shares outstanding.
What happened to NATCO Pharma Limited’s price movement after its last earnings report?
NATCO Pharma Limited reported an EPS of ₹22.85 in its last earnings report, beating expectations of ₹10.8. Following the earnings report the stock price went down -1.777%.
Which hedge fund is a major shareholder of NATCO Pharma Limited?
Currently, no hedge funds are holding shares in IN:NATCOPHARM
Company Description
NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Technical Analysis
Glenmark Pharmaceuticals Limited
―
Glenmark Life Sciences Limited
―
Jubilant Pharmova Limited
―
Marksans Pharma Limited
―
Rainbow Childrens Medicare Limited
―